CA3065086A1 - High affinity cxcr4 selective binding conjugate and method for using the same - Google Patents

High affinity cxcr4 selective binding conjugate and method for using the same Download PDF

Info

Publication number
CA3065086A1
CA3065086A1 CA3065086A CA3065086A CA3065086A1 CA 3065086 A1 CA3065086 A1 CA 3065086A1 CA 3065086 A CA3065086 A CA 3065086A CA 3065086 A CA3065086 A CA 3065086A CA 3065086 A1 CA3065086 A1 CA 3065086A1
Authority
CA
Canada
Prior art keywords
ipr
high affinity
selective binding
binding ligand
peptide conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065086A
Other languages
English (en)
French (fr)
Inventor
Junge Zhang
Liang Zeng Yan
Original Assignee
Mainline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mainline Biosciences Inc filed Critical Mainline Biosciences Inc
Publication of CA3065086A1 publication Critical patent/CA3065086A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3065086A 2017-09-05 2018-02-17 High affinity cxcr4 selective binding conjugate and method for using the same Pending CA3065086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
US62/554,354 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Publications (1)

Publication Number Publication Date
CA3065086A1 true CA3065086A1 (en) 2019-03-14

Family

ID=65635072

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065086A Pending CA3065086A1 (en) 2017-09-05 2018-02-17 High affinity cxcr4 selective binding conjugate and method for using the same

Country Status (6)

Country Link
EP (1) EP3679053A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020532496A (cg-RX-API-DMAC10.html)
KR (2) KR20230145543A (cg-RX-API-DMAC10.html)
CN (1) CN111183146A (cg-RX-API-DMAC10.html)
CA (1) CA3065086A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019050564A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
EP3956346A4 (en) * 2019-04-18 2023-01-18 Provincial Health Services Authority NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
EP4321526A4 (en) 2022-02-11 2026-04-15 C Biomex Co Ltd Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
EP4511384A4 (en) * 2022-04-20 2026-07-29 Provincial Health Services Authority Compounds targeting CXCR4, and their manufacturing and use processes
CN116023438B (zh) * 2023-02-06 2025-07-11 中国药科大学 一种cxcr4靶向多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
HRP20110551T1 (hr) * 2007-05-30 2011-09-30 Eli Lilly & Company Antagonisti cikličkog peptida cxcr4
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
MX355396B (es) * 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
CN106573959B (zh) * 2014-06-06 2022-03-25 慕尼黑工业大学 修饰的环五肽及其用途

Also Published As

Publication number Publication date
WO2019050564A1 (en) 2019-03-14
EP3679053A1 (en) 2020-07-15
CN111183146A (zh) 2020-05-19
JP2020532496A (ja) 2020-11-12
KR20230145543A (ko) 2023-10-17
EP3679053A4 (en) 2021-10-27
KR20200043970A (ko) 2020-04-28

Similar Documents

Publication Publication Date Title
EP3679053A1 (en) High affinity cxcr4 selective binding conjugate and method for using the same
JP5358564B2 (ja) 環状ペプチドｃｘｃｒ４アンタゴニスト
US11883501B2 (en) Selective CXCR4 binding peptide conjugate and methods for making and using the same
US10870681B2 (en) CXCR4 antagonists and methods of use
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
CN113024635A (zh) 一类订书肽化合物及其药物组合物的用途
WO2021150258A1 (en) Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
KR20260016965A (ko) 성장 억제호르몬 수용체 타겟팅용 펩타이드, 컨주게이트 약물 및 용도
CN120019818A (zh) 一种多肽偶联药物及其制备方法和用途
ES2367941T3 (es) Antagonistas cíclicos peptídicos de cxcr4.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230113

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20240819

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240909

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331